. 2016 Apr 26;7(23):34881–34889. doi: 10.18632/oncotarget.8993

Table 1. Characteristics of luminal breast cancer according to the lymphocyte-to-monocyte ratio.

Characteristic	Overall(%)	LMR<5.2	LMR≥5.2	P-value
Age
≤50	148 (57.1)	86	62	0.450^a
>50	111 (42.9)	59	52
Menopause status
No	146 (56.4)	84	62	0.614^a
Yes	113 (43.6)	61	52
Tumor size(cm)
<2	56 (21.6)	35	21	0.290^a
≥2	203 (78.4)	110	93
Nodal status
N0	76 (29.3)	37	39	0.133^a
N+	183 (70.7)	108	75
Histological grade
I	25 (9.7)	16	9	0.223^a
II	220 (84.9)	124	96
III	14 (5.4)	5	9
ER status
ER+	206 (79.5)	118	88	0.440^a
ER-	53 (20.5)	27	26
PR status
PR+	222 (85.7)	120	102	0.153^a
PR-	37 (14.3)	25	12
HER2 status by IHC
0/1+	216 (83.4)	126	90	0.175^a
2+	38 (14.7)	16	22
3+	5 (1.9)	3	2
Ki 67status
<20%	131 (50.6)	78	53	0.262^a
≥20%	128 (49.4)	67	61
P53 status
Positive	72 (27.8)	42	30	0.677^a
Negative	187 (72.2)	103	84
Luminal subtype
Luminal A	81 (31.3)	50	31	0.226^a
Luminal B	178 (68.7)	95	83
Chemotherapy
CEF	82 (31.7)	41	41	0.229^a
TAC	177 (68.3)	103	74
Lymphocyte count(10⁹/L)	1.76 (0.4-5.3)^*	1.59 (0.4-4)^*	1.98 (0.9-5.3)^*	0.000^b
Monocyte count (10⁹/L)	0.41 (0.1-2.2)^*	0.51(0.2-2.2)^*	0.28 (0.1-0.5)^*	0.000^b

Representing mean and range in the bracket; the mean LMR level was 5.4 (range, 0.3–27.7).

LMR, lymphocyte-to-monocyte ratio; ER, estrogen receptor; PR, progesterone receptor; HER2, human epithelial receptor 2.

Chi-square test by two-sided Pearson's exact test.

Wilcoxon rank-sum test.